

## Specialty Drug List October 2011

Abraxane Inj †	Enbrel Inj	Iprivask Inj †	Polygam Inj	Stelara Inj
Actemra Inj	Epogen Inj	Istodax Inj	Prialt Intrathecal Inj †	Stimate Nasal
Actimmune Inj	Erbix Inj †	Iveegam EN Inj	Privigen Inj	Supartz Inj
Adagen Inj	Euflexxa Inj	Ixemptra Inj †	Procrit Inj	Supprelin LA Implant
Adcirca Oral	Exjade Oral	Jevtana Inj	Profilnine Inj	Sutent Oral
Advate Inj	Extavia Inj	Kineret Inj	Prolastin Inj	Sylatron Inj
Afinitor Oral	Fabrazyme Inj	Koate - DVI Inj	Proleukin Inj †	Synagis Inj
Aldurazyme Inj	Feiba Inj	Kogenate Inj	Prolia Inj	Synvisc Inj
Alphanate Inj	Flebogamma Inj	Krystexxa Inj	Promacta Oral	Tarceva Oral
Alphanine SD Inj	Flolan Inj	Kuvan Oral	Proplex Inj	Tasigna Oral
Amevive Inj	Folotyn Inj	Letairis Oral	Protropin Inj	Temodar Oral
Ampyra Oral	Forteo Inj	Leukine Inj	Pulmozyme Inhalation	Tev-Tropin Inj
Apokyn Inj	Fragmin Inj †	Leuprolide Inj †	Qutenza Patch	Thalomid Oral
Aralast Inj	Fuzeon Inj	Lovenox Inj †	Raptiva Inj	Tobi Inhalation
Aranesp Inj	GamaSTAN Inj †	Lucentis Inj	Rebetol Oral	Torisel Inj †
Arcalyst Inj	Gamimune Inj	Lumizyme Inj	Rebetron Kit	Tracleer Oral
Arixtra Inj †	Gammagard Inj	Lupron Inj †	Rebif Inj	Treanda Inj
Arranon Inj †	Gammplex Inj	Macugen Inj	Recombinate Inj	Tykerb Oral
Arzerra Inj	Gammar Inj	Makena Inj	Refacto Inj	Tysabri Inj
Atryn Inj	Gamunex Inj	Micrhogam Inj †	Remicade Inj	Tyvaso Inhalation
Autoplex Inj	Genarc Inj	Monarc-M Inj	Remodulin Inj	Vantas Implant
Avastin Inj †	Genotropin Inj	Monoclate P Inj	Respigam Inj †	Vectibix Inj †
Avonex Inj	Geref Inj	Monomine Inj	Retisert Implant	Velcade Inj †
Baygam Inj †	Gilenya Oral	Mozobil Inj	Revatio Oral	Venoglobulin Inj
BayRHO Inj	Glassia Inj	Myozyme Inj	Revatio Inj	Ventavis Inhalation
Bebulin Inj	Gleevec Oral	Naglazyme Inj	Revlimid Oral	Vitreolis Oral
Benefix Inj	Halaven Inj	Neulasta Inj †	Rhogam Inj †	Vidaza Inj †
Benlysta Inj	H.P. Acthar Gel	Neumega Inj	Rhophylac Inj †	Vivaglobin Inj
Berinert Inj	Helixate Inj	Neupogen Inj	RiaSTAP Inj.	Vivitrol Inj
Betaseron Inj	Hemofil M Inj	Nexavar Oral	Ribapak Oral	Votrient Oral
Carbaglu Oral	Herceptin Inj †	Norditropin Inj	Ribasphere Oral	Vpriv Inj
Carimune Inj	Hizentra Inj	Novantrone Inj	Ribatab Oral	Wilate Inj
Cerezyme Inj	Humate-P Inj	Novoseven Inj	Ribavirin Oral	Winrho Inj †
Cimzia Inj	Humatrope Inj	Nplate Inj	Rituxan Inj †	Xeloda Oral †
Copaxone Inj	Humira Inj	Nutropin/AQ/Dp. Inj	Roferon A Inj	Xenazine Oral
Copegus Oral	Hyalgan Inj	Octagam Inj	Sabril Oral †	Xeomin Inj
Corifact Inj	Hyate Inj	Oforta Oral †	Saizen Inj	Xgeva Inj
Cystadane Oral	Hycamtin Oral	Omnitrope Inj	Samsca Oral	Xiaflex Inj
Cytogam Inj †	Hyperrho Inj †	Orencia Inj	Sandostatin Inj †	Xolair Inj
Cytovene Inj †	Immune Globulin	Orfadin Oral	Sensipar Oral	Xyntha Inj
Dacogen Inj †	Incivek Oral	Orthovisc Inj	Serostim Inj	Yervoy Inj
Degarelix Inj †	Increlex Inj	Ozurdex Implant	Simponi Inj	<b>Zelboraf Oral</b>
Dysport Inj	Infergen Inj	Panglobulin Inj	Soliris Inj	Zemaira Inj
Egrifta Inj	Innohep Inj †	Pegasys Inj	Somatuline Depot Inj	Zoladex Inj †
Elaprased Inj	Intron-A Inj	Peg-Intron Inj Kit	Somavert Inj	Zolinza Oral †
Eligard Inj †	Iplex Inj	Peg-Intron Inj Pen	Sprycel Oral	Zorbitive Inj
				Zytiga Oral

**Note** - Fertility related agents are **not covered** under HPL Benefit Plans.

† Products with dual access, **which are available through retail drug stores, physician offices, or Medco Specialty Pharmaceuticals †**



23 September 2011

Dear Participating Physician or Other Provider:

Enclosed with this letter please find the Health Plus of Louisiana October 2011 Specialty Drug List. This list is mailed out **quarterly**, and is adjusted to reflect the addition of specialty drugs as new drugs are released and become available. It is also available for download and printing as a \*.pdf file ([Specialty Drug List 20111001.pdf](#)) on the Health Plus web site, [www.wkhealthplus.com](http://www.wkhealthplus.com).

Health Plus uses Medco/Accredo as our exclusive Specialty Drug Vendor. **Drugs on the Specialty Drug List are reimbursed *only when ordered through Medco/Accredo Specialty Pharmacy* unless they are indicated as multisource-available by the presence of a “†” emblem by the drug’s name in the table on the opposite side of this page.** Those drugs so indicated are considered multi-source, and **may be ordered through Medco Specialty Pharmacy**, but are allowed and reimbursed when provided through Medco Retail Pharmacies, or in the case of injectables so indicated, when provided in physician offices and billed by the Participating Physician. There is a cost savings to the Plan when the drugs that are allowed as multi-source are obtained through Medco/Accredo Specialty Pharmacy. **In addition, use of the Specialty Pharmacy as a drug source eliminates the need for the physician to collect the specialty drug copay which is one hundred dollars (\$100).** The vendor of the specialty drug is responsible for collecting the copay for the specialty drug, if applicable, from the Member. Accredo collects the copayment for drugs ordered and supplied through them; physicians who supply and bill for specialty drugs that are indicated with “†” above are responsible for collecting the applicable copayment.

The changes from the previous list are:

**1. addition of Zelboraf Oral**

As has been Health Plus’s practice in the past, we try to limit changes to the Specialty Drug list as much as possible, to minimize the effort required by physician offices to comply with single-sourcing requirements. We make changes to the list primarily to add new drugs as they are released and are added to the specialty pharmacy program, but also to accomplish “housekeeping tasks” when necessary to reflect changes to availability of drugs restricted under certain manufacturer-imposed distribution limitations. Health Plus appreciates your effort and cooperation in utilizing the Specialty Pharmacy Vendor, when appropriate, as part of our joint effort to keep pharmaceuticals and specialty pharmaceuticals as an affordable benefit for our Members.

Sincerely,

A handwritten signature in blue ink, appearing to read 'Carey Allison, M.D.', written over a light blue horizontal line.

Carey Allison, M.D.  
Chief Medical Officer